Last reviewed: 16 Mar 2025
Last updated: 08 Apr 2025

Summary

Differentials

Common

  • Minimal change disease
  • Focal segmental glomerulosclerosis (FSGS)
  • Membranous nephropathy
  • Diabetic nephropathy
  • Multiple myeloma-associated AL amyloidosis
  • IgA nephropathy

Uncommon

  • Membranoproliferative (mesangiocapillary) glomerulonephritis
  • Amyloidosis
  • Lupus nephritis
  • Fabry disease
  • Alport syndrome
  • Nail-patella syndrome
  • Malignant hypertension

Contributors

Authors

Panduranga Rao, MD, DNB, MS

Richard D Swartz Collegiate Professor of Nephrology

Professor of Medicine

Department of Medicine

University of Michigan

Ann Arbor

MI

Disclosures

PR declares that he has no competing interests.

Benjamin Wagner, MD

Assistant Professor of Medicine

Department of Medicine

University of Michigan

Ann Arbor

MI

Disclosures

BW declares that he is a co-investigator on "An Open Label Phase 1b Study of Felzartamab in Lupus Nephritis", a study sponsored by HI-Bio.

Acknowledgements

Dr Panduranga Rao and Dr Benjamin Wagner would like to gratefully acknowledge Dr Ruth Pepper, Dr John Connolly, Dr David J.A. Goldsmith, Dr Oliver J. Ziff, and Dr Michael S. Gersch, previous contributors to this topic.

Disclosures

RP, JC, DJAG, OJZ, and MSG declare that they have no competing interests.

Peer reviewers

John Feehally, MBBS, FRCP

Professor of Renal Medicine

The John Walls Renal Unit

Leicester General Hospital

Leicester

UK

Disclosures

JF declares that he has no competing interests.

Judith H. Veis, MD, FASN

Associate Director

Nephrology

Washington Hospital Center

Washington

DC

Disclosures

JHV declares that she has no competing interests.

Catherine Clase, BA, MB, MSC, FRCPC

Associate Professor

Department of Medicine

McMaster University

Ontario

Canada

Disclosures

CC declares that she has no competing interests.

Use of this content is subject to our disclaimer